Ratings MorphoSys AG

Equities

MOR

DE0006632003

Market Closed - Xetra Other stock markets 16:35:30 30/04/2024 BST			5-day change	1st Jan Change
66.2 ^EUR	+0.84%		-2.29%	+94.71%

04-30	European Equities Traded in the US as American Depositary Receipts Decline	MT
04-30	MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+94.71%	2.67B	B-
IQVIA HOLDINGS INC.	+0.67%	42.19B	B
LONZA GROUP AG	+44.30%	40.15B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+6.55%	24.63B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.2B	B
MEDPACE HOLDINGS, INC.	+29.96%	12.01B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+16.03%	10.4B	B+
BIO-TECHNE CORPORATION	-4.80%	9.94B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes